Cell Reports Medicine | |
Applications of iPSC-derived beta cells from patients with diabetes | |
Jeffrey R. Millman1  Kristina G. Maxwell2  | |
[1] Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA;Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, MO 63110, USA; | |
关键词: diabetes; stem cells; differentiation; disease modeling; cell therapy; CRISPR; | |
DOI : | |
来源: DOAJ |
【 摘 要 】
Summary: Improved stem cell-derived pancreatic islet (SC-islet) differentiation protocols robustly generate insulin-secreting β cells from patient induced pluripotent stem cells (iPSCs). These advances are enabling in vitro disease modeling studies and the development of an autologous diabetes cell replacement therapy. SC-islet technology elucidates key features of human pancreas development and diabetes disease progression through the generation of pancreatic progenitors, endocrine progenitors, and β cells derived from diabetic and nondiabetic iPSCs. Combining disease modeling with gene editing and next-generation sequencing reveals the impact of diabetes-causing mutations and diabetic phenotypes on multiple islet cell types. In addition, the supply of SC-islets, containing β and other islet cell types, is unlimited, presenting an opportunity for personalized medicine and overcoming several disadvantages posed by donor islets. This review highlights relevant studies involving iPSC-β cells and progenitors, encompassing new conclusions involving cells from patients with diabetes and the therapeutic potential of iPSC-β cells.
【 授权许可】
Unknown